Lutz Frolich
Overview
Explore the profile of Lutz Frolich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
8430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vollhardt A, Frolich L, Stockbauer A, Danek A, Schmitz C, Wahl A
Neurobiol Dis
. 2025 Feb;
208:106845.
PMID: 39999928
Alzheimer's disease (AD) and vascular dementia (VaD) together contribute to almost 90 % of all dementia cases leading to major health challenges of our time with a substantial global socioeconomic...
2.
Benson G, Bartels C, Stamatis F, Belz M, Esselmann H, Frolich L, et al.
Geriatrics (Basel)
. 2025 Feb;
10(1).
PMID: 39997520
: Mild cognitive impairment (MCI) is a heterogeneous clinical syndrome and is important for the diagnosis and management of Alzheimer's disease (AD). With the expansion of biomarker-based diagnostics, the aim...
3.
Muller J, Elsaesser M, Berger R, Muller W, Hellmich M, Zehender N, et al.
Am J Geriatr Psychiatry
. 2025 Jan;
PMID: 39884877
Objective: This study investigates the association of loneliness during the COVID-19 pandemic and the course of depressive, anxiety and sleep symptoms after psychological treatment in older adults. Methods: During the...
4.
Aye S, Johansson G, Hock C, Lannfelt L, Sims J, Blennow K, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100022.
PMID: 39800469
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in...
5.
Handels R, Hataiyusuk S, Wimo A, Skoldunger A, Bakker C, Bieber A, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100015.
PMID: 39800459
Introduction: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe. Methods: A secondary analysis...
6.
Macfarlane S, Grimmer T, Teo K, OBrien T, Woodward M, Grunfeld J, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100016.
PMID: 39800452
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD). Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available...
7.
San Nicolo M, Mertzig S, Berghaus A, Peters O, Frolich L, Grimmer T, et al.
Methods
. 2025 Jan;
234:233-241.
PMID: 39755347
Background: Diagnostics for neurodegenerative diseases lack non-invasive approaches suitable for early-stage biochemical screening and routine examination of neuropathology. Biomarkers of neurodegenerative diseases pass through the brain-nose interface (BNI) and accumulate...
8.
Rune Nielsen T, de Mendonca A, Frolich L, Engelborghs S, Gove D, Lamirel D, et al.
Int J Geriatr Psychiatry
. 2024 Dec;
39(12):e70034.
PMID: 39663199
Objectives: There is no European consensus on good clinical practice for timely diagnosis and culturally appropriate care of people with dementia from minority ethnic groups. Despite significant advances in culture-sensitive...
9.
Jessen F, Frolich L, Hort J, Winblad B, Fortea J
Lancet
. 2024 Nov;
404(10468):2161-2162.
PMID: 39551061
No abstract available.
10.
Mattke S, Tang Y, Hanson M, von Arnim C, Frolich L, Grimmer T, et al.
J Alzheimers Dis
. 2024 Sep;
101(4):1249-1259.
PMID: 39302379
Background: Amyloid-targeting therapies for Alzheimer's disease (AD) might become available in Germany soon. The combination of a large pool of prevalent cases and a complex diagnostic process to determine eligibility...